Effects of different progesterone levels on reproductive outcomes in assisted reproductive technologies: from molecular basis to treatment strategies

References

• Szegeczki V, Fazekas L, Kulcsár M, et al. Endometrium as control of endometriosis in experimental research: assessment of sample suitability. Diagnostics (Basel). 2022;12(4):1.
   Google Scholar
• Genazzani AD, Podfigurna-Stopa A, Czyzyk A, et al. Short-term estriol administration modulates hypothalamo-pituitary function in patients with functional hypothalamic amenorrhea (FHA). Gynecol Endocrinol. 2016;32(3):253–8.
   PubMed Web of Science ®Google Scholar
• Dodson WC, Olive DL, Hughes CL, et al. The prognostic value of serum concentrations of progesterone, estradiol, and luteinizing hormone during superovulation with and without adjunctive leuprolide therapy. Fertil Steril. 1993;59(6):1174–1178.
   PubMed Web of Science ®Google Scholar
• Elnashar AM. Progesterone rise on the day of HCG administration (premature luteinization) in IVF: an overdue update. J Assist Reprod Genet. 2010;27(4):149–155.
   PubMed Web of Science ®Google Scholar
• de Mouzon J, Goossens V, Bhattacharya S, et al., The European IVF-monitoring (EIM) Consortium, for the European Society of Human Reproduction and Embryology (ESHRE). Assisted reproductive technology in Europe, 2006: results generated from european registers by ESHRE. Hum Reprod. 2010;25(8):1851–1862.
   PubMed Web of Science ®Google Scholar
• Chambers GM, Paul RC, Harris K, et al. Assisted reproductive technology in Australia and New Zealand: cumulative live birth rates as measures of success. Med J Aust. 2017;207(3):114–118.
   PubMed Web of Science ®Google Scholar
• Baethge C, Goldbeck-Wood S, Mertens S. SANRA—a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4(1):5.
   PubMedGoogle Scholar
• Bosch E, Labarta E, Crespo J, et al. Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles. Hum Reprod. 2010;25(8):2092–2100.
   PubMed Web of Science ®Google Scholar
• Hill MJ, Royster GD, Healy MW, et al. Are good patient and embryo characteristics protective against the negative effect of elevated progesterone level on the day of oocyte maturation? Fertil Steril. 2015;103(6):1477–1484.e1-5.
   PubMed Web of Science ®Google Scholar
• Hill MJ, Healy MW, Richter KS, et al. Defining thresholds for abnormal premature progesterone levels during ovarian stimulation for assisted reproduction technologies. Fertil Steril. 2018;110(4):671–679.e2.
   PubMed Web of Science ®Google Scholar
• Koo HS, Cha SH, Kim HO, et al. A high response to controlled ovarian stimulation induces premature luteinization with a negative impact on pregnancy outcomes in a gonadotropin-releasing hormone antagonist cycle. Clin Exp Reprod Med. 2015;42(4):149–155.
   PubMedGoogle Scholar
• Kyrou D, Al-Azemi M, Papanikolaou EG, et al. The relationship of premature progesterone rise with serum estradiol levels and number of follicles in GnRH antagonist/recombinant FSH-stimulated cycles. Eur J Obstet Gynecol Reprod Biol. 2012;162(2):165–168.
   PubMed Web of Science ®Google Scholar
• Oktem O, Akin N, Bildik G, et al. FSH stimulation promotes progesterone synthesis and output from human granulosa cells without luteinization. Hum Reprod. 2017;32(3):643–652.
   PubMed Web of Science ®Google Scholar
• Papaleo E, Corti L, Vanni VS, et al. Basal progesterone level as the main determinant of progesterone elevation on the day of hCG triggering in controlled ovarian stimulation cycles. Arch Gynecol Obstet. 2014;290(1):169–176.
   PubMed Web of Science ®Google Scholar
• Venetis CA, Kolibianakis EM, Bosdou JK, et al. Estimating the net effect of progesterone elevation on the day of hCG on live birth rates after IVF: a cohort analysis of 3296 IVF cycles. Hum Reprod. 2015;30(3):684–691.
   PubMed Web of Science ®Google Scholar
• Werner MD, Forman EJ, Hong KH, et al. Defining the “sweet spot” for administered luteinizing hormone-to-follicle-stimulating hormone gonadotropin ratios during ovarian stimulation to protect against a clinically significant late follicular increase in progesterone: an analysis of 10,280 first in vitro fertilization cycles. Fertil Steril. 2014;102:1312–1317.
   PubMed Web of Science ®Google Scholar
• Blockeel C, Baumgarten M, De Vos M, et al. Administration of gnrh antagonists in case of elevated progesterone at initiation of the cycle: a prospective cohort study. Curr Pharm Biotehnol. 2011;12(3):423–428.
   PubMed Web of Science ®Google Scholar
• Hamdine O, Macklon NS, Eijkemans MJC, et al. Elevated early follicular progesterone levels and in vitro fertilization outcomes: a prospective intervention study and meta-analysis. Fertil Steril. 2014;102(2):448–454.e1.
   PubMed Web of Science ®Google Scholar
• Kolibianakis EM, Zikopoulos K, Smitz J, et al. Elevated progesterone at initiation of stimulation is associated with a lower ongoing pregnancy rate after IVF using GnRH antagonists. Hum Reprod. 2004;19(7):1525–1529.
   PubMed Web of Science ®Google Scholar
• Mutlu MF, Erdem M, Mutlu I, et al. Elevated basal progesterone levels are associated with increased preovulatory progesterone rise but not with higher pregnancy rates in ICSI cycles with GnRH antagonists. Eur J Obstet Gynecol Reprod Biol. 2017;216:46–50.
   PubMed Web of Science ®Google Scholar
• Sims JA, Seltman HJ, Muasher SJ. Early follicular rise of serum progesterone concentration in response to a flare-up effect of gonadotrophin-releasing hormone agonist impairs follicular recruitment for in-vitro fertilization. Hum Reprod. 1994;9(2):235–240.
   PubMed Web of Science ®Google Scholar
• Tang Y, Gong F, Lin G, et al. Early follicular progesterone concentrations and in vitro fertilization pregnancy outcomes. Fertil Steril. 2007;87(4):991–994.
   PubMed Web of Science ®Google Scholar
• Angioni S, Portoghese E, Milano F, et al. Diagnosis of metabolic disorders in women with polycystic ovary syndrome. Obstet Gynecol Surv. 2008;63(12):796–802.
   PubMed Web of Science ®Google Scholar
• Angioni S, Sanna S, Magnini R, et al. The quantitative insulin sensitivity check index is not able to detect early metabolic alterations in young patients with polycystic ovarian syndrome. Gynecol Endocrinol. 2011;27(7):468–474.
   PubMed Web of Science ®Google Scholar
• D’Alterio MN, Sigilli M, Succu AG, et al. Pregnancy outcomes in women with polycystic ovarian syndrome. Minerva Obstet Gynecol. 2022;74(1):45–59.
   PubMedGoogle Scholar
• van der Linden M, Buckingham K, Farquhar C, et al. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015;2015: CD009154.
   PubMedGoogle Scholar
• Fauser BCJM, Devroey P. Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow? Fertil Steril. 2005;83(6):1607–1611.
   PubMed Web of Science ®Google Scholar
• Vitale SG, Fulghesu AM, Mikuš M, et al. The translational role of miRNA in polycystic ovary syndrome: from bench to Bedside-A systematic literature review. Biomedicines. 2022;10(8):1816.
   PubMed Web of Science ®Google Scholar
• Tsai T-E, Lin P-H, Lian P-F, et al. Artificial oocyte activation may improve embryo quality in older patients with diminished ovarian reserve undergoing IVF-ICSI cycles. J Ovarian Res. 2022;15(1):102.
   PubMed Web of Science ®Google Scholar
• Šprem Goldštajn M, Dumančić S, Mikuš M. Retrospective analysis of the use of two recombinant follitropin alfa injections in patients undergoing in vitro fertilization treatment with the gonadotropin‐releasing hormone antagonist protocol. J Obstet Gynaecol Res. 2021;47(3):992–1001.
   PubMed Web of Science ®Google Scholar
• Tesarik J, Hazout A, Mendoza C. Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Hum Reprod. 2004;19(5):1176–1180.
   PubMed Web of Science ®Google Scholar
• Fulghesu AM, Piras C, Dessì A, et al. Urinary metabolites reveal hyperinsulinemia and insulin resistance in polycystic ovarian syndrome (PCOS. Metabolites. 2021;11(7):437.)
   PubMed Web of Science ®Google Scholar
• Angioni S, Cofelice V, Sedda F, et al. Progestins for symptomatic endometriosis: results of clinical studies. Curr Drug Ther. 2015;10(2):91–104.
   Google Scholar
• Šprem Goldštajn M, Mikuš M, Ćorić M, et al. The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: a report of the literature. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):553–558.
   PubMed Web of Science ®Google Scholar
• Trounson AO, Calabrese R. Changes in plasma progesterone concentrations around the time of the luteinizing hormone surge in women superovulated for in vitro fertilization. J Clin Endocrinol Metab. 1984;59(6):1075–1080.
   PubMed Web of Science ®Google Scholar
• Fleming R, Coutts JR. Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppression. Fertil Steril. 1986;45(2):226–230.
   PubMed Web of Science ®Google Scholar
• Macnamee MC, Howles CM, Edwards RG. Pregnancies after IVF when high tonic LH is reduced by long-term treatment with GnRH agonists. Hum Reprod. 1987;2(7):569–571.
   PubMed Web of Science ®Google Scholar
• Alessandro P, Luigi N, Felice S, et al. Research development of a new GnRH antagonist (elagolix) for the treatment of endometriosis: a review of the literature. Arch Gynecol Obstet. 2017;295(4):827–832.
   PubMed Web of Science ®Google Scholar
• Fulghesu AM, Angioni S, Belosi C, et al. Pituitary?ovarian response to the gonadotrophin-releasing hormone-agonist test in anovulatory patients with polycystic ovary syndrome: predictive role of ovarian stroma. Clin Endocrinol. 2006;65(3):396–401.
   PubMed Web of Science ®Google Scholar
• Fleming R, Adam AH, Barlow DH, et al. A new systematic treatment for infertile women with abnormal hormone profiles. BJOG. 1982;89(1):80–83.
   Google Scholar
• Urbancsek J, Rabe T, Grunwald K, et al. Analysis of hormonal changes during combined buserelin/HMG treatment. Hum Reprod. 1990;5(6):675–681.
   PubMed Web of Science ®Google Scholar
• Fanchin R, Righini C, Olivennes F, et al. Premature progesterone elevation does not alter oocyte quality in in vitro fertilization. Fertil Steril. 1996;65(6):1178–1183.
   PubMed Web of Science ®Google Scholar
• Adda-Herzog E, Poulain M, de Ziegler D, et al. Premature progesterone elevation in controlled ovarian stimulation: to make a long story short. Fertil Steril. 2018;109(4):563–570.
   PubMed Web of Science ®Google Scholar
• Florio P, Imperatore A, Litta P, et al. The use of nomegestrol acetate in rapid preparation of endometrium before operative hysteroscopy in pre-menopausal women. Steroids. 2010;75(12):912–917.
   PubMed Web of Science ®Google Scholar
• Al-Azemi M, Kyrou D, Kolibianakis EM, et al. Elevated progesterone during ovarian stimulation for IVF. Reprod Biomed Online. 2012;24(4):381–388.
   PubMed Web of Science ®Google Scholar
• Silverberg KM, Martin M, Olive DL, et al. Elevated serum progesterone levels on the day of human chorionic gonadotropin administration in in vitro fertilization cycles do not adversely affect embryo quality. Fertil Steril. 1994;61(3):508–513.
   PubMed Web of Science ®Google Scholar
• Bila J, Dotlic J, Radjenovic SS, et al. Predictive value of basal serum progesterone for successful IVF in endometriosis patients: the need for a personalized approach. J Pers Med. 2022;12(10):1639.
   PubMed Web of Science ®Google Scholar
• Huang JC, Jackson KV, Hornstein MD, et al. The effect of elevated serum progesterone during ovulation induction in in vitro fertilization-embryo transfer. J Assist Reprod Genet. 1996;13(8):617–624.
   PubMed Web of Science ®Google Scholar
• Vitale SG, Palumbo M, Rapisarda AMC, et al. Use of pentoxifylline during ovarian stimulation to improve oocyte and embryo quality: a retrospective study. J Gynecol Obstet Hum Reprod. 2022;51(6):102398.
   PubMedGoogle Scholar
• Faulisi S, Reschini M, Borroni R, et al. Clinical value of basal serum progesterone prior to initiate ovarian Hyper-Stimulation with GnRH antagonists: a retrospective cohort study. Gynecol Obstet Invest. 2017;82(2):175–180.
   PubMed Web of Science ®Google Scholar
• Ovarian Stimulation T, Bosch E, Broer S, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI†. Hum Reprod Open. 2020;2020:hoaa009.
   PubMedGoogle Scholar
• Santos-Ribeiro S, Polyzos NP, Haentjens P, et al. Live birth rates after IVF are reduced by both low and high progesterone levels on the day of human chorionic gonadotrophin administration. Hum Reprod. 2014;29(8):1698–1705.
   PubMed Web of Science ®Google Scholar
• Arvis P, Lehert P, Guivarc’h-Levêque A. Both high and low HCG day progesterone concentrations negatively affect live birth rates in IVF/ICSI cycles. Reprod Biomed Online. 2019;39(5):852–859.
   PubMed Web of Science ®Google Scholar
• Venetis CA, Kolibianakis EM, Bosdou JK, et al. Progesterone elevation and probability of pregnancy after IVF: a systematic review and meta-analysis of over 60 000 cycles. Hum Reprod Update. 2013;19(5):433–457.
   PubMed Web of Science ®Google Scholar
• Labarta E, Martínez-Conejero JA, Alamá P, et al. Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: a functional genomics analysis. Hum Reprod. 2011;26(7):1813–1825.
   PubMed Web of Science ®Google Scholar
• Van Vaerenbergh I, Fatemi HM, Blockeel C, et al. Progesterone rise on HCG day in GnRH antagonist/rFSH stimulated cycles affects endometrial gene expression. Reprod Biomed Online. 2011;22(3):263–271.
   PubMed Web of Science ®Google Scholar
• Patton PE, Lim JY, Hickok LR, et al. Precision of progesterone measurements with the use of automated immunoassay analyzers and the impact on clinical decisions for in vitro fertilization. Fertil Steril. 2014;101(6):1629–1636.
   PubMed Web of Science ®Google Scholar
• Thomsen LH, Kesmodel US, Andersen CY, et al. Daytime variation in serum progesterone During the Mid-Luteal phase in women undergoing In vitro fertilization treatment. Front Endocrinol (Lausanne). 2018;9:92.
   PubMed Web of Science ®Google Scholar
• Peluso C, R de O, Laporta GZ, et al. Are ovarian reserve tests reliable in predicting ovarian response? Results from a prospective, cross-sectional, single-center analysis. Gynecol Endocrinol. 2021;37(4):358–366.
   PubMed Web of Science ®Google Scholar
• Terzic M, Aimagambetova G, Garzon S, et al. Ovulation induction in infertile women with endometriotic ovarian cysts: current evidence and potential pitfalls. Minerva Med. 2020;111(1):50–61.
   PubMed Web of Science ®Google Scholar
• Di Paola R, Garzon S, Giuliani S, et al. Are we choosing the correct FSH starting dose during controlled ovarian stimulation for intrauterine insemination cycles? Potential application of a nomogram based on woman’s age and markers of ovarian reserve. Arch Gynecol Obstet. 2018;298(5):1029–1035.
   PubMed Web of Science ®Google Scholar
• Vitale SG, Palumbo M, Conde-López C, et al. Effect of growth hormone administration on ICSI outcomes in patients with polycystic ovary syndrome and recurrent implantation failure: a retrospective cross-over study. Int J Gynecol Obstet. 2021;153(2):357–358.
   PubMed Web of Science ®Google Scholar
• Ali D-E-S, Shah M, Ali A, et al. Treatment with metformin and combination of metformin Plus pioglitazone on serum levels of IL-6 and IL-8 in polycystic ovary syndrome: a randomized clinical trial. Horm Metab Res. 2019;51:714–722.
   PubMed Web of Science ®Google Scholar
• Vignali M, Belloni GM, Pietropaolo G, et al. Effect of dienogest therapy on the size of the endometrioma. Gynecol Endocrinol. 2020;36(8):723–727.
   PubMed Web of Science ®Google Scholar
• Kyrou D, Kolibianakis EM, Fatemi HM, et al. High exposure to progesterone between the end of menstruation and the day of triggering final oocyte maturation is associated with a decreased probability of pregnancy in patients treated by in vitro fertilization and intracytoplasmic sperm injection. Fertil Steril. 2011;96(4):884–888.
   PubMed Web of Science ®Google Scholar
• Huang C-C, Lien Y-R, Chen H-F, et al. The duration of pre-ovulatory serum progesterone elevation before hCG administration affects the outcome of IVF/ICSI cycles. Hum Reprod. 2012;27(7):2036–2045.
   PubMed Web of Science ®Google Scholar
• Griesinger G, Mannaerts B, Andersen CY, et al. Progesterone elevation does not compromise pregnancy rates in high responders: a pooled analysis of in vitro fertilization patients treated with recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in six trials. Fertil Steril. 2013;100(6):1622–1628.e1-3.
   PubMed Web of Science ®Google Scholar
• Xu B, Li Z, Zhang H, et al. Serum progesterone level effects on the outcome of in vitro fertilization in patients with different ovarian response: an analysis of more than 10,000 cycles. Fertil Steril. 2012;97(6):1321–1327.e1-4.
   PubMed Web of Science ®Google Scholar
• Bozdag G, Turkyilmaz E, Yildiz S, et al. Progesterone elevation and preventive strategies to avoid implantation failure. Semin Reprod Med. 2019;37:265–272.
   PubMed Web of Science ®Google Scholar
• Fanchin R, Righini C, Olivennes F, et al. Computerized assessment of endometrial echogenicity: clues to the endometrial effects of premature progesterone elevation. Fertil Steril. 1999;71(1):174–181.
   PubMed Web of Science ®Google Scholar
• Chetkowski RJ, Kiltz RJ, Salyer WR. In premature luteinization, progesterone induces secretory transformation of the endometrium without impairment of embryo viability. Fertil Steril. 1997;68(2):292–297.
   PubMed Web of Science ®Google Scholar
• Gizzo S, Andrisani A, Esposito F, et al. Which luteal phase support is better for each IVF stimulation protocol to achieve the highest pregnancy rate? A superiority randomized clinical trial. Gynecol Endocrinol. 2014;30(12):902–908.
   PubMed Web of Science ®Google Scholar
• Artini PG, Volpe A, Angioni S, et al. A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program. J Endocrinol Invest. 1995;18(1):51–56.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Angioni S, Spedicato M, et al. Uterine contractility is strongly influenced by steroids and glucose metabolism: an in vitro study on bovine myometrium. Gynecol Endocrinol. 2011;27(9):636–640.
   PubMed Web of Science ®Google Scholar
• Haouzi D, Bissonnette L, Gala A, et al. Endometrial receptivity profile in patients with premature progesterone elevation on the day of HCG administration. Biomed Res Int. 2014;2014:1–10.
   Web of Science ®Google Scholar
• Peiretti M, Congiu F, Ricciardi E, et al. Conservative treatment for well-differentiated endometrial cancer: when and why it should be considered in young women. eCancer. 2019;13:892.
   PubMed Web of Science ®Google Scholar
• Lahoud R, Kwik M, Ryan J, et al. Elevated progesterone in GnRH agonist down regulated in vitro fertilisation (IVFICSI) cycles reduces live birth rates but not embryo quality. Arch Gynecol Obstet. 2012;285(2):535–540.
   PubMed Web of Science ®Google Scholar
• Harada T, Yoshida S, Katagiri C, et al. Reduced implantation rate associated with a subtle rise in serum progesterone concentration during the follicular phase of cycles stimulated with a combination of a gonadotrophin-releasing hormone agonist and gonadotrophin. Hum Reprod. 1995;10(5):1060–1064.
   PubMed Web of Science ®Google Scholar
• Harada T, Katagiri C, Takao N, et al. Altering the timing of human chorionic gonadotropin injection according to serum progesterone (P) concentrations improves embryo quality in cycles with subtle P rise. Fertil Steril. 1996;65(3):594–597.
   PubMed Web of Science ®Google Scholar
• Melo MAB, Meseguer M, Garrido N, et al. The significance of premature luteinization in an oocyte-donation programme. Hum Reprod. 2006;21:1503–1507.
   PubMed Web of Science ®Google Scholar
• Ubaldi F, Smitz J, Wisanto A, et al. Oocyte and embryo quality as well as pregnancy rate in intracytoplasmic sperm injection are not affected by high follicular phase serum progesterone. Hum Reprod. 1995;10(12):3091–3096.
   PubMed Web of Science ®Google Scholar
• Fanchin R, de Ziegler D, Taieb J, et al. Premature elevation of plasma progesterone alters pregnancy rates of in vitro fertilization and embryo transfer. Fertil Steril. 1993;59(5):1090–1094.
   PubMed Web of Science ®Google Scholar
• Corti L, Papaleo E, Pagliardini L, et al. Fresh blastocyst transfer as a clinical approach to overcome the detrimental effect of progesterone elevation at hCG triggering: a strategy in the context of the italian law. Eur J Obstet Gynecol Reprod Biol. 2013;171(1):73–77.
   PubMed Web of Science ®Google Scholar
• Kiliçdag EB, Haydardedeoglu B, Cok T, et al. Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles. Arch Gynecol Obstet. 2010;281(4):747–752.
   PubMed Web of Science ®Google Scholar
• Huang B, Ren X, Wu L, et al. Elevated progesterone levels on the day of oocyte maturation may affect top quality embryo IVF cycles. PLoS One. 2016;11(1):e0145895.
   PubMed Web of Science ®Google Scholar
• Vanni VS, Somigliana E, Reschini M, et al. Top quality blastocyst formation rates in relation to progesterone levels on the day of oocyte maturation in GnRH antagonist IVF/ICSI cycles. PLoS One. 2017;12(5):e0176482.
   PubMed Web of Science ®Google Scholar
• Racca A, Santos-Ribeiro S, De Munck N, et al. Impact of late-follicular phase elevated serum progesterone on cumulative live birth rates: is there a deleterious effect on embryo quality? Hum Reprod. 2018;33(5):860–868.
   PubMed Web of Science ®Google Scholar
• Oudendijk JF, Yarde F, Eijkemans MJC, et al. The poor responder in IVF: is the prognosis always poor?: a systematic review. Hum Reprod Update. 2012;18(1):1–11.
   PubMed Web of Science ®Google Scholar
• Beckers NGM, Macklon NS, Eijkemans MJC, et al. Women with regular menstrual cycles and a poor response to ovarian hyperstimulation for in vitro fertilization exhibit follicular phase characteristics suggestive of ovarian aging. Fertil Steril. 2002;78(2):291–297.
   PubMed Web of Science ®Google Scholar
• Zajec V, Mikuš M, Vitale SG, et al. Current status and challenges of drug development for hormonal treatment of endometriosis: a systematic review of randomized control trials. Gynecological Endocrinology. 2022;38(9):713–720.
   PubMed Web of Science ®Google Scholar
• Angioni S, Pontis A, Malune ME, et al. Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study. Gynecol Endocrinol. 2020;36(1):84–86.
   PubMed Web of Science ®Google Scholar
• Fanchin R, Hourvitz A, Olivennes F, et al. Premature progesterone elevation spares blastulation but not pregnancy rates in in vitro fertilization with coculture. Fertil Steril. 1997;68(4):648–652.
   PubMed Web of Science ®Google Scholar
• Acharya KS, Acharya CR, Bishop K, et al. Freezing of all embryos in in vitro fertilization is beneficial in high responders, but not intermediate and low responders: an analysis of 82,935 cycles from the society for assisted reproductive technology registry. Fertil Steril. 2018;110(5):880–887.
   PubMed Web of Science ®Google Scholar
• Muzii L, DI Tucci C, Galati G, et al. The role of microbiota in female fertility and infertility. Minerva Obstet Gynecol. 2022;74(5):419–433.
   PubMedGoogle Scholar
• Esteves SC, Khastgir G, Shah J, et al. Association Between progesterone elevation on the day of human chronic gonadotropin trigger and pregnancy outcomes After fresh embryo transfer in In vitro fertilization/intracytoplasmic sperm injection cycles. Front Endocrinol (Lausanne). 2018;9:201.
   PubMed Web of Science ®Google Scholar